Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Acetaminophen  COVID-19 treatment studies for Acetaminophen  C19 studies: Acetaminophen  Acetaminophen   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -224% Improvement Relative Risk Ventilation -434% Progression -244% Progression (b) -201% Hospitalization time -100% c19early.com/ace Manjani et al. Acetaminophen for COVID-19 LATE Favors acetaminophen Favors control
Manjani, 524 patient acetaminophen late treatment study: 224% higher mortality [p=0.001], 434% higher ventilation [p=0.001], 244% higher progression [p=0.005], and 100% longer hospitalization [p=0.001] https://c19p.org/manjani
copied to clipboard
Effects of acetaminophen on outcomes in patients hospitalized with COVID-19
Manjani et al., Chest, doi:10.1016/j.chest.2021.07.992
31 Oct 2021    Source   PDF   Share   Tweet
Retrospective 524 hospitalized patients in the USA, showing higher mortality and progression with acetaminophen use.
risk of death, 223.5% higher, RR 3.24, p = 0.001, treatment 388, control 136.
risk of mechanical ventilation, 434.5% higher, RR 5.34, p < 0.001, treatment 388, control 136.
risk of progression, 244.0% higher, OR 3.44, p < 0.005, treatment 132, control 136, triaged to higher level of care, high exposure, RR approximated with OR.
risk of progression, 201.0% higher, OR 3.01, p < 0.007, treatment 256, control 136, triaged to higher level of care, moderate exposure, RR approximated with OR.
hospitalization time, 100% higher, relative time 2.00, p < 0.001, treatment 388, control 136.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Manjani et al., 31 Oct 2021, retrospective, USA, peer-reviewed, 6 authors, study period February 2020 - June 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAcetaminophenAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit